Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer

Journal of Oncology Practice

Volumn 3, Issue 4, 2007, Pages 182-186

  Oratz, Ruth ^a,b   Paul, Dev ^a,b   Cohn, Allen L ^a,b   Sedlacek, Scot M ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKY MOUNTAIN CANCER CENTERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SIZE; CANCER STAGING; CLINICAL DECISION MAKING; COMMUNITY CARE; CORRELATION ANALYSIS; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIXED TUMOR; MUCINOUS CARCINOMA; PROGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT PLANNING;

EID: 42649098952     PISSN: 15547477     EISSN: None     Source Type: Journal    
DOI: 10.1200/JOP.0742001     Document Type: Article

References (10)

1. Mincey BA, Palmieri FM, Perez EA: Adjuvant therapy for breast cancer: Recommendations for management based on consensus review and recent clinical trials. Oncologist 7: 246-250, 2002
2. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
3. Kramer CY: Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12: 307-310, 1956
4. Mehla CR, Nitin R, Gray R: Computing an exact confidence interval for the common odds rato in several 2 × 2 contingency tables. J Am Stat Assoc 80: 969-973, 1985
5. Habel LA, Shak S, Jacobs MK, et al: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25, 2006; http://breast-cancer-research.com/content/8/3/R25
6. Robins P, Pinder S, de Klerk N, et al: Histological grading of breast carcinomas: A study of interobserver agreement. Hum Pathol 26: 873-879, 1995
7. Hanrahan EO, Valero V, Gonzalez-Angulo A, et al: Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bNOMO): A review of the literature. J Clin Oncol 224: 2113-2122, 2006
8. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-Gene RT-PCR assay in lymph-node-negative, estrogen receptor-positive early-stage breast cancer. Am J Manag Care 11: 313-324, 2005
9. Bryant J: Is the "standard adjuvant regimen" good for all? Presented at the 9th International Conference of Primary Therapy of Early Breast Cancer, St Gallen, Switzerland, January 26-29, 2005
10. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 224: 3726-3734, 2006